Amarin begins legally promoting off-label uses of its prescription fish-oil drug, while Pacira sues the FDA over the label for its pain drug, Exparel.
Ashley Madison's lesson must be heeded. For all the good pharma has done for the world, it has also created its share of ethical quagmires.
The deal is expected to complement the company's digital health platform.
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.
With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.
Despite increasing income, many doctors are turning away from self-employment.
Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.
Though it's unlikely that patient portals will ever be accessed as often as mobile banking, ensuring that the patient portal provides obvious value to a patient's experience with a healthcare provider remains an important point.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
A recent Medscape survey found that under-40s were more likely to work for a healthcare organization than were their older colleagues, trading autonomy for work-life balance and income predictability.
The third lifestyle survey shows that doctors are battling the bulge just like everyone else.
A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
Growing client demand encouraged the agency to make its HCP content capabilities official.
Researchers say we've been overestimating how many NPs and PAs can be expected to ease the inflow of just-insured patients, while another study shows just why they may be bypassing independent practices.
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
A CME activity was associated with increased testing that could head off neuropathy in patients with type 2 diabetes.
Medscape asked and doctors shared what they hate about most medical apps, Livestrong merch hits the clearance rack, healthcare reform savings begin to surface, Lilly releases early RA drug trial results
JAMA's look into the impact of patient centric care shows that a broader scope is needed to understand the financial and health impact of active patients and how doctors perceive what it means to be engaged with patients.
Pharmas are spending far less on reprints and far more on digital promotion to physicians and other healthcare professionals, according to a healthcare media buying specialist.
Two studies show that it's not enough to focus on cost to alter healthcare.
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
The most effective journal ads of the year included executions for Pradaxa, Humira and Conceptus' Essure Procedure, according to the Doctors' Choice Study.
An adherence study found that when doctors laid out the whys and hows of prescribed medications, patients were more likely to take them. Other reports suggest that the communication gap is about more than the medication— including such factors as pricing, a desire for control, and undisclosed medical information.
Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive, which found Advair, Spiriva and Mirena to be tops in their categories with doctors.
A recent paper shows licensing boards may take action for a professional's behavior regardless of whether it is in the context of a professional setting.
For the drug industry, the big news in the "fiscal cliff" deal is that the next big congressional showdown—one that could have big implications for the healthcare industries—has been kicked down the road a couple months.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.